A neuropeptide with diverse biological activities
货号:ajcx23550
CAS:N/A
分子式:C25H30D4F2O5
分子量：456.6
溶解度:DMF: 30 mg/ml,DMSO: 30 mg/ml,Ethanol: 30 mg/ml
纯度：98%
存储：Store at -20°C
库存：现货

Background:

Tafluprost-d₄contains four deuterium atoms at the 3', 3', 4', and 4' positions. It is intended for use as an internal standard for the quantification of tafluprost by GC- or LC-mass spectrometry. A number of 17-phenyl trinor prostaglandin F_2αderivatives have been approved for the treatment of glaucoma.^1,2,3,4Of these, the ones wherein the 13,14-double bond has been hydrogenated retain relatively good potency, but show a significantly reduced incidence of local irritant side effects.⁵Alternatively, it was recently reported that analogs incorporating a 15-deoxy-15,15-difluoro modification also had a favorable ophthalmic activity profile.⁶Tafluprost is a 2-series, 16-phenoxy analog of PGF_2αwith the 15,15-difluoro substitution. Tafluprost free acid is a very potent FP receptor agonist, with a K_ivalue of 0.4 nM.⁶The ester prodrug forms of tafluprost are also potent ocular hypotensives in monkeys.

1.Woodward, D.F., Krauss, A.H.P., Chen, J., et al.The pharmacology of Bimatoprost (LumiganTM)Survey of Ophthalmology45S337-S345(2001) 2.Abramovitz, M., Adam, M., Boie, Y., et al.The utilization of recombinant prostanoid receptors to determine the affinities and selectivities of prostaglandins and related analogsBiochim. Biophys. Acta1483(2)285-293(2000) 3.Sorbera, L.A., and CastaÑer, J.TravoprostDrugs Future25(1)41-45(2000) 4.Maxey, K.M., Johnson, J., Camras, C.B., et al.The hydrolysis of bimatoprost in corneal tissue generates a potent prostanoid FP receptor agonistSuv. Ophthalmol.47(4)S34-S40(2002) 5.Resul, B., Stjernschantz, J., No, K., et al.Phenyl-substituted prostaglandins: Potent and selective antiglaucoma agentsJournal of Medicinal Chemistry36243-248(1993) 6.Nakajima, T., Matsugi, T., Goto, W., et al.New fluoroprostaglandin F2α derivatives with prostanoid FP-receptor agonistic activity as potent ocular-hypotensive agentsBiological and Pharmaceutical Bullentin26(12)1691-1695(2003)